Dolutegravir, a newly approved anti-HIV medication is insoluble in the normal gastric pH range and that results in slow onset of action. The research proposes cocrystallization process to increase the solubility of the drug and hence dissolution. The cocrystals of dolutegravir were formulated using methionine as coformers by solvent evaporation method. The cocrystals were evaluated for solubility, in vitro drug release, and solid-state characterization, study. The orodispersible tablets of dolutegravir cocrystal were successfully prepared by direct compression method. The solid-state characterization study showed the compatibility and amorphization of the drug in the cocrystal form. The cocrystal of drug: methionine (1:2) was found to enhance dissolution by 1.88 times compared to the pure drug. The orodispersible tablets disintegrated at 10.05 secs and 90% drug was released in 20 min. Hence, it can be concluded that the methionine-dolutegravir cocrystal can be a promising means to improve the solubility of the drug
Dolutegravir CoCrystal Solubility enhancement orodispersible tablet dissolution
not applicable
Birincil Dil | İngilizce |
---|---|
Konular | İlaç Dağıtım Teknolojileri |
Bölüm | Araştırma Makalesi |
Yazarlar | |
Yayımlanma Tarihi | 25 Mart 2025 |
Gönderilme Tarihi | 15 Temmuz 2024 |
Kabul Tarihi | 18 Kasım 2024 |
Yayımlandığı Sayı | Yıl 2025 Cilt: 50 Sayı: 1 |